Vetoquinol Aktie

Business Wire 12.09.2024 17:48 Uhr 227 Leser Artikel bewerten: (1) Vetoquinol: 2024 Half-year Results Sales: 264m (+3.2% as reported) Essential products sales: €160m (+6.0% as reported) Net income, Group share: €24m (9.0% of sales) EBITDA: €45m (17.0% of sales) Cash flow generation: €27m Regulatory News: The Board of Directors of Vetoquinol SA (Paris:VETO) met on September 10, 2024 to review business activity and approve the financial statements for the first half of 2024. The auditors have released their first half limited review report. Vetoquinol reported sales of €264 million for the first 6 months of FY 2024, up +3.2% on a reported basis. Further simplification of the Complementary products range resulted in a voluntary decline of around 1,6% in sales for the 1st half of FY 2024. The currency impact is insignificant (-0.3 M€) at the end of June 2024 vs. -2.0 M€ for the same period of FY 2023. Sales of Essential products totaled €160m, up +6.0% on a reported basis, and accounted for 61% of the Group's sales in H1 2024 vs. 59% in H1 2023. Essential products, the main driver of the Group's strategy, continues to lead Vetoquinol's development. At June 30, 2024, almost all the Group's strategic countries were up from the first half 2023. This is the fruit of the ongoing work of our teams in the field. The Europe strategic territory grew by +5.0% on a reported basis, with the return of volume growth. This is the result of the sustained performance of Essentials products in the Group's first territory. The Asia/Pacific/Rest of World territory grew by 10.0% on a reported basis. The Americas, i.e. Canada, Brazil and Mexico, were also up. In the United States, on the other hand, the expected landing after several years of strong growth was harder than anticipated. This was due to a decline in inventories at American wholesalers, coupled with the temporary unavailability of a product range. These factors had a negative impact of -8.7% on sales in this territory. Sales of products for companion animals (€188m) were up +3.8% on a reported basis and accounted for 71.2% of the group's total sales (vs. €181m in H1 2023). Farm animals products came to €76 million, up +1.8% on a reported basis (vs. €75 million in H1 2023). Gross margin on purchases was 72.3%, slightly up on the H1 2023 figure. This trend is linked to the product mix, and in particular to the continued growth of Essential products, as well as to selling price increases of over +3%. These factors offset the rise in purchasing costs for raw materials and outsourced manufacturing. Other external purchases and expenses rose sharply by +20.8% (vs. -7.9% in H1 2023), i.e. +€10.3m without any significant currency impact, reflecting increased R&D and marketing expenditure (+€9.0m). Personnel costs were up +€4.3m, reflecting salary inflation applied in the Group. Total headcount is up slightly: 2,519 at June 30, 2024 vs. 2,497 at June 30, 2023. Depreciation and amortization charges linked to IFRS 16 generated a depreciation charge of -3.0 million vs. -2.9 million at June 30, 2023. EBIT before amortization of intangible assets acquired amounted to €38.5 million for the year ended June 30, 2024, representing 14.6% of total sales. Group operating income recurring was €32 million (12.1% of sales). Other operating income and expenses amounted to €1.1m, compared with €2.6m at June 30, 2023. This net income relates to the sale of an industrial site in Brazil. As a reminder, the net income of €2.6 million recorded at June 30, 2023 included a renegotiation of the acquisition price of Clarion (Brazilian subsidiary) and reflected an uncertain local macro-economic situation. Income tax expense for H1 2024 was -€11.2m (vs. -€10.4m in H1 2023). The apparent tax rate was 32.0% (vs. 24.4% at end June 2023). Vetoquinol's EBITDA stood at €45 million at June 30, 2024, (17.0% of sales). It has been impacted by the drop in business in the United States, by the increased pace of R&D spending (8.1% of sales vs. 6.9% of sales in H1 2023) to support the Group's development, and by the decision to commit a significant portion of the annual marketing budget in the first half of the year. Net income for the Vetoquinol Group amounted to €24 million, or 9.0% of H1 2024 sales. weiter hier: https://www.finanznachrichten.de/nachrichten-2024-09/63247407-vetoquinol-2024-half-year-results-004.htm

https://www.ariva.de/news/vetoquinol-sales-1st-quarter-2024-134m-11228229

https://www.businesswire.com/news/home/20220923005285/en/

https://de.marketscreener.com/kurs/aktie/VETOQUINOL-SA-36676/news/Vetoquinol-SA-berichtet-uber-die-Ergebnisse-fur-das-Halbjahr-bis-zum-30-Juni-2022-41802277/ Vetoquinol SA berichtet über die Ergebnisse für das Halbjahr bis zum 30. Juni 2022 15.09.2022 | 21:20 Vetoquinol SA hat die Ergebnisse für das Halbjahr zum 30. Juni 2022 bekannt gegeben. Für das Halbjahr meldete das Unternehmen einen Umsatz von 270,76 Millionen Euro gegenüber 255,33 Millionen Euro vor einem Jahr. Der Nettogewinn belief sich auf 21,4 Millionen Euro gegenüber 36,19 Millionen Euro vor einem Jahr. Der unverwässerte Gewinn je Aktie aus dem fortgeführten Geschäft betrug 1,81 EUR gegenüber 3,06 EUR im Vorjahr. Das verwässerte Ergebnis je Aktie aus fortgeführten Geschäftsbereichen betrug 1,83 EUR gegenüber 3,07 EUR im Vorjahr.